ArticleFrontiers in microbiology2025
High genome diversity of
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Methods: From February 2023 to February 2024, 117 KP isolates were collected from a Chinese traditional medicine hospital in Jiangsu province, China. Antimicrobial susceptibility testing and whole-genome sequencing were performed on all isolates. Then, capsular serotype, multi-locus sequence typing, virulence genes, and resistance genes were identified using Prokka and Kleborate software tools. The hypermucoviscosity phenotype was detected using the string test. Antimicrobial susceptibility was tested following the guidelines by the Clinical and Laboratory Standards Institute, using a commercially prepared and dehydrated panel. A chi-squared test was performed to assess the differences in virulence gene profiles between hypermucoviscous and non-hypermucoviscous isolates. Results: A high resistance rate to ampicillin (98.7%) and doxycycline (41.0%) was observed in the KP strains. The resistance rate to cephalosporins ranged from 10 to 20%, and 23.7% of the strains were multidrug-resistant (MDR). A total of 66 resistance genes from 13 categories were identified, including carbapenem-resistant genes in four KP strains. The most common capsular serotypes were K1 and K2 (24.0% of the isolates). O1 was the dominant O antigen type (52.1%). The KP strains were classified into 62 sequence types (STs), with ST23, ST29, ST412, and ST111 being the most prevalent (each accounting for >5.0% of the isolates). The carriage rates of the virulence genes aerobactin, yersiniabactin, colibactin, salmochelin, RmpADC, and RmpA2 were 44.4, 47.9, 11.1, 54.7, 55.6, and 31.6%, respectively. All ST23 KP strains carried virulence plasmids other than RmpADC. Hypermucoviscous (HM) KP was observed in 23.4% of the isolates. HM KP strains carried a higher number of virulence genes compared to the non-HM KP strains. Conclusion: Although no single dominant (KP) clone, serotype, or sequence type was identified among the isolated KP strains from this hospital, the overall resistance rates remained relatively low. However, the relatively prevalent ST23 KP strains, which carry multiple virulence genes, are a concern due to their potential to acquire carbapenem-resistant genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.